Comparison · NCT00494481-c72334d0
Vandetanib Plus Docetaxel vs Placebo Plus Docetaxel: Number of Patients With a Disease Progression Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib Plus Docetaxel vs Placebo Plus Docetaxel: Number of Patients With a Disease Progression Event. Trial comparisons, record NCT00494481-c72334d0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00494481-c72334d0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.686 | 0.52 | 0.814 | wilson | |
| Risk in group 2 | 0.621 | 0.44 | 0.773 | wilson | |
| Risk difference, group 1 minus group 2 | 0.065 | -0.16 | 0.287 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.769 | 1.59 | log | |
| Odds ratio, group 1 over group 2 | 1.33 | 0.473 | 3.75 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib Plus Docetaxel than on Placebo Plus Docetaxel | 15.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib Plus Docetaxel | vandetanib 100 mg plus docetaxel | 24 | 35 | OG000 |
| Group 2 | Placebo Plus Docetaxel | placebo plus docetaxel | 18 | 29 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients With a Disease Progression Event
- Description
- Number of patients with objective disease progression or death (by any cause in the absence of objective progression)
- Time frame
RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off
- Population
Source ClinicalTrials.gov
Trial
- Title
- E3 Breast Cancer Taxotere Combination
- NCT number
- NCT00494481
- Phases
- PHASE2
- Conditions
- Advanced Breast Cancer
- Interventions
- Vandetanib (ZD6474), Docetaxel
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00494481?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00494481-c72334d0